SLC5A2 and heart failure: The use of novel heart failure-specific agents was comparatively low, with only 40% of patients receiving sodium/glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) and 21.1% receiving dual-acting angiotensin receptor-neprilysin inhibitors (ARNI).